




Improving performance and landmark wins in a challenging market

Interim Review, January–September 2025

October 29, 2025

Thomas Hinnerskov, President and CEO

Katri Hokkanen, CFO

Agenda

Interim Review, January–September 2025

1 Q3/2025 highlights and strategy execution

2 Financial development

3 Guidance and short-term market outlook



Q3/2025 highlights and strategy execution

Q3/2025 highlights

- **Orders received increased organically by 7% and were EUR 1.1 billion**, a solid achievement considering the overall subdued market environment
- **Process Performance Solutions continued on a strong growth track**, delivering 11% organic growth in orders received
- **Large tissue order** from the U.S., setting a new benchmark and opening robust lifecycle opportunities
- **Q3 market environment:** Continued good demand in Process Performance Solutions contrasted with weaker market conditions in Biomaterials Solutions and Services
- **Best third quarter ever in Comparable EBITA and margin:** EUR 159 million and 12.3%, slightly higher than Q3/24
- **‘Lead the Way’ strategy execution** started and first concrete benefits realized through savings from operating model renewal
- **2025 guidance unchanged:** Both net sales and comparable EBITA to remain at the previous year’s level

Lead the Way strategy execution underway

➤ **Lead the Way strategy launched in June 2025**

- Operating model and reporting structure now in place
- Teams aligning around lifecycle value creation and supply chain excellence

➤ **Leadership strengthened**

- New EVP appointed for Tissue business
- Key L3-level hires made to support execution

➤ **Targeting EUR 80 million in annual savings from operating model renewal**


- Approximately EUR 15 million savings realized in Q3
- Full run-rate expected from early 2026

➤ **Customer response has been positive**

- Lifecycle approach and regenerative purpose resonate well
- Strategy supports long-term value creation and performance

Orders received increased organically by 7% and were EUR 1.1 billion in Q3/2025, Process Performance Solutions' growth continued

Orders received (EUR million and organic growth y/y)



- Four consecutive quarters of organic growth is a good achievement in the current market environment
- 11% organic growth in Process Performance Solutions compared with Q3/2024 driven by solid market and strategic wins
- Record-breaking quarter in Tissue, but overall Biomaterial Solutions and Services was impacted by softer market conditions
- These results support a strong order backlog and provide good foundation for Q4/25 and 2026

Expanding the reach of Valmet's automation solutions

Automation for 20 MW hydrogen fuel cell facility in Naepo New Town

- Demonstrates versatility of Valmet's automation in clean-energy applications beyond traditional pulp & paper
- Strengthens our position in Asia's energy transition and important step for future hydrogen projects
- Strengthens Valmet's automation installed base and recurring lifecycle revenues in global process industries
- Aligned with Process Performance Solutions' strategic growth priorities
- End user: Naepo Green Energy, adding hydrogen to an existing 500 MW LNG plant
- Repeat business with Lotte Engineering & Construction
- Scope: Valmet automation technology (DCS) to ensure reliability and efficiency for 48 fuel cells



Process Performance Solutions: Strong performance in Q3

Strong growth in orders received

- Orders received increased to EUR 345 million
- Orders received organic growth was 11%
- Organic growth was 16% in Automation Solutions and 9% in Flow Control, driven by good demand and pricing


Net sales increased organically

- Net sales amounted to EUR 361 million
- Net sales organic growth was 5%
- Organic growth was 7% in Automation Solutions and 4% in Flow Control


Comparable EBITA margin to new record

- Comparable EBITA increased to EUR 79 million and margin to 21.9%
- The margin increase reflects disciplined commercial execution, savings from the operating model renewal, and improved performance in the acquired operations


Orders received (EUR million and growth y/y)



Net sales (EUR million and growth y/y)



Comparable EBITA (EUR million and % of net sales)



Landmark U.S. tissue win strengthens Valmet's market position and lifecycle opportunities

Strategic impact


- Expands North American installed base, unlocking recurring lifecycle revenue
- Strengthens Valmet's leadership in ultra-premium tissue segment
- Deepens the 30-year partnership with Sofidel, a leading global tissue producer

Financial impact

- Record-high order value, included in Q3 2025 orders received
- Revenue recognized over project execution (2025–2028)
- Lifecycle services expected to generate additional long-term growth and margin after start-up

Project scope and execution

- Extended scope drives customer value and includes tissue line, automation, flow control, auxiliary systems and industrial internet solutions
- Start-up scheduled for Q2 2028



Valmet's ADT (Advantage ThruAir) tissue machine. The new production line will have a width of 5.6 meters and an annual production capacity of 75,000 tons - a typical size for a large high-end tissue machine.

Biomaterial Solutions and Services: Landmark tissue win, margin pressure in a softer market

Orders received growth supported by landmark tissue mill win


- Orders received amounted EUR 738 million
- Orders received increased organically by 5%
- Service orders were flat (+1%) organically, driven by growth in mill improvements and field services
- Biomaterial services market slowed down from the high H1/25 level
- Orders in Consumables and performance parts decreased

Net sales decreased

- Net sales amounted to EUR 934 million
- Net sales remained at the previous year's level (+1%) organically
- Service net sales remained at the previous year's level (+2%) organically

Comparable EBITA and margin decreased

- Comparable EBITA decreased to EUR 89 million and margin was 9.5%
- Despite cost benefits from the operating model change, the margin was lower across the project portfolio




■ Biomaterial services



Financial development

Net sales and Comparable EBITA


Net sales (EUR million and organic growth y/y)



Net sales stable at EUR 1.3 billion

- Currency headwind of roughly EUR 31 million
- Organic net sales 2% higher than Q3/2024
- Stable development in both segments

Comparable EBITA (EUR million and % of net sales)




Record-high Q3 in Comparable EBITA margin

- Comparable EBITA was EUR 159 million and margin 12.3%
- Increase was driven by the strong performance in Process Performance Solutions and roughly EUR 15 million cost savings from the operating model renewal

Order backlog amounted to EUR 4.5 billion at the end of Q3/2025


Order backlog (EUR million) and book-to-bill (orders received / net sales)




- Order backlog was EUR 74 million higher than at the end of 2024
- Solid order backlog and book-to-bill ratio create a good foundation going into Q4/25 and 2026
- Based on our current delivery schedules, we expect that roughly EUR 3.6 billion of the order backlog will be recognized as net sales in Q4/25 and 2026

Strong cash conversion ratio in line with long-term historical average

Cash flow from operating activities (EUR million)



Net working capital and orders received (EUR million)



- Cash flow from operating activities amounted to EUR 94 million in Q3/2025
- Cash conversion¹ ratio was 92% in Q3/25 LTM, in line with long-term historical average
- Net working capital amounted³ to EUR -76 million (EUR 32 million), which equals -1% (1%) of last 12 months orders received
- CAPEX² amounted to EUR -81 million (EUR -77 million) in Q1-Q3/25 and represented 2.2% of net sales


1) Cash conversion ratio calculated as cash flow from operating activities / Comparable EBITA

2) Excluding business combinations and right-of-use assets.


3) Net working capital includes EUR 123 million dividend liability (second EUR 0.67 installment was paid in October 7, 2025)

Gearing decreased from the previous quarter's level

Net debt (EUR million) and gearing (%)



Net debt to EBITDA* ratio




- Net debt was EUR 945 million and gearing decreased from Q2/2025 to 38%
- Net debt to EBITDA* ratio decreased to 1.50 from Q2/2025
- The average interest rate of Valmet's total debt remained at the Q2/2025 level and was 3.6% at the end of Q3/2025
- Net financial expenses amounted to EUR -13 million in Q3/2025 (EUR -17 million in Q3/2024)

*Last twelve months (LTM) EBITDA


Capital employed, Comparable ROCE and EPS

Capital employed (EUR million) and Comparable ROCE (%)



- The acquisitions of Analyzer Products and Integration in 2024 and Tissue Converting in 2023, and the integration of Flow Control into Valmet in 2022 have increased capital employed

Adjusted EPS, EUR



- Adjusted EPS decrease was mainly related to restructuring expenses of the operating model renewal

Adjusted earnings per share is an alternative performance measure that excludes the impact of fair value adjustments arising from business combinations, net of tax.

Key figures

EUR million	Q3/2025	Q3/2024	Change	Q1–Q3/2025	Q1–Q3/2024	Change
Orders received	1,083	1,041	4%	3,936	3,374	17%
Order backlog ¹				4,526	3,536	28%
Net sales	1,295	1,295	0%	3,720	3,831	-3%
Comparable EBITA	159	156	2%	423	417	1%
% of net sales	12.3%	12.0%	0.2 pp	11.4%	10.9%	0.5 pp
EBITA	149	138	8%	343	384	-11%
Operating profit (EBIT)	125	109	14%	271	299	-9%
Profit before taxes	112	92	21 %	227	250	-9%
Effective tax rate, % ²	23.4%	26.6%		22.9%	27.1%	
Adjusted earnings per share, EUR ³	0.54	0.49	11%	1.18	1.33	-12%
Earnings per share, EUR	0.46	0.37	26%	0.95	0.99	-4%
Comparable ROCE, LTM ⁴				13.1%	13.2%	-0.1 pp
Cash flow from operating activities	94	110	-14%	391	376	4%
Net debt to EBITDA ⁵ ratio				1.50	1.59	
Gearing ¹				38%	43%	-4.4 pp

Items affecting comparability: EUR -10 million in Q3/2025 (EUR -17 million in Q3/2024) and EUR -80 million in Q1–Q3/2025 (EUR -33 million in Q1–Q3/2024).

1) At end of period

2) Calculated as (income taxes during the period / profit before taxes for the period) x 100%

3) Adjusted earnings per share excludes the impact of fair value adjustments arising from business combinations, net of tax

4) Comparable return on capital employed (ROCE) before taxes, LTM (last twelve months)

5) Last twelve months (LTM) EBITDA



Guidance and short-term market outlook

Guidance and short-term market outlook

Guidance for 2025

Guidance



Valmet reiterates its guidance issued on February 13, 2025, in which Valmet estimates that net sales in 2025 will remain at the previous year's level in comparison with 2024 (EUR 5,359 million) and Comparable EBITA in 2025 will remain at the previous year's level in comparison with 2024 (EUR 609 million).

Short-term market outlook for October 2025 - March 2026

Process Performance Solutions

Valmet estimates that the market environment will remain stable. However, uncertainty related to global economic outlook remains high.

Biomaterial Solutions and Services

Uncertainty on global economic outlook remains high and continues to impact customers' decision making, capacity utilization rates and profitability levels.

Valmet sees a risk of further softening in the biomaterial services market in the coming quarters.

It is also typical that individual large investment decisions by customers can influence the overall market significantly within a single quarter.

The short-term market outlook is given for October 2025 – March 2026 compared with July–September 2025. Valmet's estimate of the expected growth rate of its key markets, based on ongoing discussions with customers and other market information. The outlook excludes normal seasonal variation in Valmet's business and should not be interpreted as guidance for Valmet's own orders received.

Q&A

Financial Statements Review for 2025

February 6, 2026

www.valmet.com/investors

Important notice

IMPORTANT: The following applies to this document, the oral presentation of the information in this document by Valmet (the “Company”) or any person on behalf of the Company, and any question-and-answer session that follows the oral presentation (collectively, the “Information”). In accessing the Information, you agree to be bound by the following terms and conditions.

The Information is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident of, or located in, any locality, state, country or other jurisdiction where such distribution or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. The Information is not for publication, release or distribution in the United States, the United Kingdom, Australia, Canada or Japan.

The Information does not constitute or form part of and should not be construed as an offer or the solicitation of an offer to subscribe for or purchase any securities, and nothing contained therein shall form the basis of or be relied on in connection with any contract or commitment whatsoever, nor does it constitute a recommendation regarding any securities. Prospective investors are required to make their own independent investigations and appraisals of the business and financial condition of the Company before taking any investment decision with respect to securities of the Company.

No securities of the Company are being offered or sold, directly or indirectly, in or into the United States and no shares in the Company have been, or will be, registered under the Securities Act of 1933, as amended (the “Securities Act”), or under the securities laws of any state of the United States and, accordingly, may not be offered or sold, directly or indirectly, in or into the United States (as defined in Regulation S under the Securities Act), unless registered under the Securities Act or pursuant to an exemption from the registration requirements of the Securities Act and in compliance with any applicable state securities laws of the United States.

The Information is directed solely at: (i) persons outside the United Kingdom, (ii) persons with professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 as amended (the “Order”), (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order and (iv) persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any securities of the Company or any member of its group may otherwise lawfully be communicated or caused to be communicated (all such persons in (i)-(iv) above being “Relevant Persons”). Any investment activity to which the Information relates will only be available to and will only be engaged with Relevant Persons. Any person who is not a Relevant Person should not act or rely on the Information. By accessing the Information, you represent that you are a Relevant Person.

The Information contains forward-looking statements. All statements other than statements of historical fact included in the Information are forward-looking statements. Forward-looking statements give the Company’s current expectations and projections relating to its financial condition, results of operations, plans, objectives, future performance and business. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company’s control that could cause the Company’s actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company’s present and future business strategies and the environment in which it will operate in the future.


No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the Information or the opinions contained therein. The Information has not been independently verified and will not be updated. The Information, including but not limited to forward-looking statements, applies only as of the date of this document and is not intended to give any assurances as to future results. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to the Information, including any financial data or forward-looking statements, and will not publicly release any revisions it may make to the Information that may result from any change in the Company’s expectations, any change in events, conditions or circumstances on which these forward-looking statements are based, or other events or circumstances arising after the date of this document. Market data used in the Information not attributed to a specific source are estimates of the Company and have not been independently verified.



Appendix


Valmet in Q3/2025

Orders received




■ Process Performance Solutions
■ Biomaterial Solutions and Services

Net sales



■ Process Performance Solutions
■ Biomaterial Solutions and Services

Comparable EBITA (excl. Other)



■ Process Performance Solutions
■ Biomaterial Solutions and Services

Orders received EUR 1,083 million	Net sales EUR 1,295 million	Comparable EBITA EUR 159 million	Comparable EBITA margin 12.3%	Order backlog EUR 4,526 million	Employees 18,842
--------------------------------------	--------------------------------	-------------------------------------	----------------------------------	------------------------------------	---------------------

Segment key figures

Orders received, EUR million	Q3/2025	Q3/2024	Change	Q1–Q3/2025	Q1–Q3/2024	Change
Process Performance Solutions	345	322	7%	1,128	1,002	13%
Biomaterial Solutions and Services	738	719	3%	2,808	2,372	18%
Total	1,083	1,041	4%	3,936	3,374	17%


Net sales, EUR million	Q3/2025	Q3/2024	Change	Q1–Q3/2025	Q1–Q3/2024	Change
Process Performance Solutions	361	354	2%	1,072	1,013	6%
Biomaterial Solutions and Services	934	941	-1%	2,649	2,818	-6%
Total	1,295	1,295	0%	3,720	3,831	-3%

Comparable EBITA, EUR million	Q3/2025	Q3/2024	Change	Q1–Q3/2025	Q1–Q3/2024	Change
Process Performance Solutions	79	65	22%	200	174	15%
Biomaterial Solutions and Services	89	101	-12%	258	276	-7%
Other	-9	-10	-9%	-34	-32	6%
Total	159	156	2%	423	417	1%


Comparable EBITA margin, % of net sales	Q3/2025	Q3/2024	Change	Q1–Q3/2025	Q1–Q3/2024	Change
Process Performance Solutions	21.9%	18.3%	3.5 pp	18.7%	17.1%	1.5 pp
Biomaterial Solutions and Services	9.5%	10.7%	-1.2 pp	9.7%	9.8%	-0.1 pp
Total	12.3%	12.0%	0.2 pp	11.4%	10.9%	0.5 pp

Comparable gross profit and SG&A expenses development


Comparable gross profit
(EUR million and % of net sales)




Comparable SG&A expenses
(EUR million and % of net sales)



Long-term development of Valmet's orders received, EUR million



Long-term development of Valmet's net sales, EUR million



Long-term development of Valmet's Comparable EBITA and margin

EUR million and % of net sales

